Which patients is Lucius version of Upatinib suitable for, and how much can it cost?

Upadatinib is a JAK inhibitor, mainly used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, etc. Its mechanism of action is to selectively inhibit JAK enzyme, which can effectively regulate immune responses, thereby alleviating symptoms and improving patients' quality of life. In recent years, with the increase in patients with autoimmune diseases, upadatinib has received widespread attention and has gradually become a new choice for clinical treatment. In particular, the generic version of upadatinib launched by Laos Lucius Company provides patients with an affordable treatment option, allowing more patients to enjoy the benefits of this therapy.

Specific indications for Lucius version of upadatinib include: adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or are intolerant to one or moreTNF blockers; one or more TNF blockers Adult patients with active psoriatic arthritis who have insufficient response or intolerance to larders; adult and pediatric patients aged 12 years and above with refractory, moderate to severe atopic dermatitis, for whom other systemic pharmaceutical products (including biologics) cannot effectively control the disease or are inappropriate Use of these therapies; Adult patients with active ulcerative colitis who have had an inadequate response to or intolerance to one or more TNF blockers; Adult patients with active Crohn's disease who have had an inadequate response to or intolerance to one or more TNF blockers; Adult patients who have had an inadequate response to or intolerance to one or more TNF blockers; Adult patients with active ankylosing spondylitis who have an inadequate response to or intolerance to multiple TNF blockers; adults with active non-radiation axial arthropathy (nr-axSpA) with objective signs of inflammation who have an inadequate response to or intolerance to TNF blocker therapy.

As for the price, the current specification of the generic version of Upatinib produced by Lucius in Laos is A box of 15mg*30 tablets sells for about 500 to 600 RMB. Compared with the original version, this price is more economical and affordable, making it affordable for many patients. And this version has been approved by the Lao government and is a officially marketed drug.

In short, the Lucius version of upadatinib provides many patients with a new treatment option with its affordable price and good quality. However, it is worth noting that there are certain risks associated with purchasing overseas medicines. In order to ensure the quality and safety of medicines, patients must choose guaranteed and formal channels to purchase them.

References:

https://www.drugs.com/history/rinvoq.html